✦ LIBER ✦

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

✍ Scribed by Simon Heller; John Buse; Miles Fisher; Satish Garg; Michel Marre; Ludwig Merker; Eric Renard; David Russell-Jones; Areti Philotheou; Ann Marie Ocampo Francisco; Huiling Pei; Bruce Bode

Book ID: 117309861
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 271 KB
Volume: 379
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(12)60204-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Insulin degludec, an ultra-longacting ba

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

✍ Alan J Garber; Allen B King; Stefano Del Prato; Seamus Sreenan; Mustafa K Balci; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 284 KB

Comparison of insulin detemir and insuli

Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial

✍ Simon Heller; Christoph Koenen; Bruce Bode 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 237 KB

Insulin degludec, an ultra-long-acting b

Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial

✍ Bernard Zinman; Greg Fulcher; Paturi V Rao; Nihal Thomas; Lars A Endahl; Thue Jo 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 203 KB

Efficacy and safety of insulin degludec

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

✍ Zinman, Bernard; DeVries, J Hans; Bode, Bruce; Russell-Jones, David; Leiter, Law 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 337 KB

Long-term efficacy and safety of insulin

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial

✍ P. C. Bartley; M. Bogoev; J. Larsen; A. Philotheou 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB